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Abstract 
Coronary 18F-sodium fluoride (18F-NaF) positron emission tomography (PET) and computed 
tomography (CT) angiography-based quantitative plaque analysis have shown promise in 
refining risk stratification in patients with coronary artery disease. We combined both of these 
novel imaging approaches to develop an optimal machine-learning model for the future risk of 
myocardial infarction in patients with stable coronary disease.  
Methods  
Patients with known coronary artery disease underwent coronary 18F-NaF PET and CT 
angiography on a hybrid PET/CT scanner. Machine-learning by extreme gradient boosting was 
trained using clinical data, CT quantitative plaque analysis measures and 18F-NaF PET, and it 
was tested using repeated 10-fold hold-out testing.  
Results 
Among 293 study participants (65±9 years; 84% male), 22 subjects experienced a myocardial 
infarction over the 53 [40-59] months of follow-up. On univariable receiver-operator-curve 
analysis, only 18F-NaF coronary uptake emerged as a predictor of myocardial infarction (c-
statistic 0.76, 95% confidence interval (CI) 0.68-0.83). When incorporated into machine-learning 
models, clinical characteristics showed limited predictive performance (c-statistic 0.64, 95% CI 
0.53-0.76;) and were outperformed by a quantitative plaque analysis-based machine-learning 
model (c-statistic 0.72, 95% CI 0.60-0.84). After inclusion of all available data (clinical, 
quantitative plaque and 18F-NaF PET), we achieved a substantial improvement (p=0.008 versus 
18F-NaF PET alone) in the model performance (c-statistic 0.85, 95% CI 0.79-0.91).  
Conclusions 
Both 18F-NaF uptake and quantitative plaque analysis measures are additive and strong 
predictors of outcome in patients with established coronary artery disease. Optimal risk 
stratification can be achieved by combining clinical data with these approaches in a machine-
learning model. 
Keywords: coronary artery disease, computed tomography, 18F-NaF positron emission 







In every day clinical practice, prediction of myocardial infarction is challenging and is typically 
based on cardiovascular risk factors and scores, especially in subjects with suspected coronary 
artery disease (1). However, in patients with established coronary artery disease, the performance 
of risk scores is limited with c-statics ranging from 0.60 to 0.68 (1). Recently, advanced imaging 
techniques have demonstrated considerable promise in refining risk stratification in patients with 
established coronary artery disease. We have demonstrated that assessment of disease activity in 
the coronary arteries with 18F-sodium fluoride (18F-NaF) positron emission tomography (PET) 
outperforms clinical variables and risk scores for the prediction of myocardial infarction in 
patients with a high burden of coronary artery disease (2,3). Similarly, in observational studies 
and a sub-analysis of the SCOT-HEART trial, quantitative plaque analysis investigating both 
plaque type and burden on contrast enhanced CT angiography has emerged as a major predictor 
of adverse outcomes (4,5). To date, no study has investigated whether these two promising 
methods (which can be obtained during a single imaging session on a hybrid PET/CT scanner) 
are interchangeable or can provide superior predictive performance when used in combination.  
In this study, we employed machine-learning to investigate whether the prognostic information 
provided by quantitative CT plaque analysis and assessments of disease activity by 18F-NaF PET 
are complementary, and to develop an optimized model to determine the future risk of 




The current study is based on a cohort of patients with established coronary artery disease on 
guideline recommended medical treatments which we assembled for our previous publication 
regarding the prognostic utility of 18F-NaF PET (2). However, in the current study, we have 
included longer follow-up and utilized novel quantitative plaque analysis of coronary CT 
angiography. Our work is focused specifically upon whether machine learning methods can 
combine the prognostic information provided by clinical factors, quantitative CT plaque analysis 
and 18F-NaF PET to improve the prediction of myocardial infarction. All participants underwent 
hybrid coronary 18F-NaF PET and contrast CT coronary angiography within prospective 
observational research studies (NCT01749254, NCT02110303, NCT02607748) (3,7,8). All 
patients had established coronary artery disease and underwent a comprehensive baseline clinical 
assessment with evaluation of their cardiovascular risk factor profile including calculation of the 
Secondary Manifestations of ARTerial disease (SMART) risk score (Supplementary Material) 
(1). Studies were conducted with the approval of the local research ethics committee, in 
accordance with the Declaration of Helsinki, and with written informed consent from each 
participant. 
CT Angiography and 18F-Sodium Fluoride PET 
Acquisition and Reconstruction 
Patients underwent 18F-NaF PET on hybrid PET/CT scanners (128-slice Biograph mCT, Siemens 
Medical Systems, Knoxville, USA or Discovery 710 GE Healthcare, Milwaukee, WI, USA) 60 
min following intravenous administration of 18F-NaF (250 MBq). We acquired a non-contrast CT 
attenuation correction scan followed by a 30-min PET emission scan in list mode, a low-dose 
non-contrast ECG-gated CT for calculation of the coronary calcium and a contrast-enhanced 
ECG-gated coronary CT angiogram (CTA) which was obtained in mid-diastole and end-
expiration on the same PET/CT system without repositioning the patient. The ECG-gated PET 
list mode dataset was reconstructed using harmonized protocols as described previously 
(supplementary material) (8-10).  
Coronary microcalcification activity (CMA) quantification 
Image analysis was performed in FusionQuant (Cedars-Sinai Medical Center, Los Angeles) (11). 
We used a recently described measure of coronary 18F-NaF uptake, coronary microcalcification 
activity (CMA) that quantifies PET activity across the entire coronary vasculature (12). CMA is 
a highly reproducible and robust measure of disease activity predicting both disease progression 
and myocardial infarction (2, 13). We calculated the per vessel and per patient CMA (Figure 1), 
maximum coronary SUV and target to background ratio (TBR) as described previously 
(supplementary material) (3, 12). 
Computed Tomography 
The coronary artery calcium score was measured in Agatston units (AU) using clinical software 
(NetraMD, ScImage, Los Altos, CA, USA) on non-contrast CT scans. The presence, extent and 
severity of coronary artery disease were evaluated on contrast-enhanced CT angiography by 
defining the segment involvement score, DUKE coronary artery disease index and the number of 
vessels with >50% luminal stenosis (14). Multivessel coronary artery disease was defined as at 
least 2 major epicardial vessels with any combination of either >50% stenosis, or previous 
revascularization.  
Quantitative Plaque Analysis of CT angiography  
We performed quantitative plaque analysis of all coronary segments with a lumen diameter 
greater than 2 mm using semi-automated software (AutoPlaque version 2.0, Cedars-Sinai 
Medical Center, Los Angeles, USA) (4,5). Proximal and distal limits of lesions were manually 
marked by an experienced reader (physicians with several years of experience in clinical 
coronary CT image analysis) after examination of coronary CT angiography images in 
multiplanar format. Subsequent plaque quantification was fully automated using adaptive scan-
specific thresholds. Total, calcified, non-calcified as well as low attenuation plaque volumes 
were calculated. The plaque burden was calculated according to the following equation (plaque 
volume x 100%/vessel volume). The contrast density difference was the maximal difference in 
contrast density (mean Hounsfield unit / cross-sectional area) in the plaque and the reference 
proximal vessel cross section. 
Machine-learning 
Machine learning was used to derive a joint score for myocardial infarction by incorporating the 
key clinical variables, quantitative CT variables, and 18F-NaF PET findings.    
Model Building 
XGBoost is a recent implementation of a gradient boosting algorithm, which iteratively trains a 
set of weak learners (simple decision trees) using a given set of patient data, to build a combined 
strong classifier to identify an outcome (15). For every patient, the XGBoost algorithm computes 
an individualized probability of outcome, considering all input variables.  
We applied XGBoost for prediction of myocardial infarction by building 3 models. First, a 
clinical model with baseline clinical characteristics: age, gender, co-morbidities, medication, 
biomarkers, past medical history and coronary calcium score (model 1). The second model was 
derived from quantitative plaque analysis variables (including low attenuation plaque burden and 
the contrast density difference). A final model incorporated clinical, CT and 18F-NaF PET data in 
combination. All variables utilized in the machine-learning modelling are presented in 
Supplementary Table 1.  
Model Testing  
Given the limited number of cases, we refrained from performing data-specific hypertuning and 
applied fixed XGBoost parameters established in our previous studies (15). Furthermore, to 
avoid biased results and limit overfitting, we tested all of our models using repeated 10-fold 
cross-testing, which separates training and testing data (16). The dataset was randomly split into 
10 folds with similar myocardial infarction rates in each fold (stratified 10 folds). Ten models 
were created each from 90% of the data, and each tested in held-out test sample (10% of the 
data). These 10 held-out samples containing non-overlapping test results were subsequently 
concatenated to evaluate the average performance of XGBoost in unseen data.  
Feature importance  
To elucidate the influence of each of the variables included in the machine-learning model, we 
provided machine-learning feature importance scores. Importance is the relative amount that 
each attribute improves the XGBoost performance measure (similar to information gain). The 
variable importance was determined directly from the xgboost model separately in each fold and 
returned from the XGBoost model for each variable (17). 
Clinical follow-up 
The primary endpoint of the study was fatal or non-fatal myocardial infarction. Outcome 
information was obtained in June 2020 from the local and national healthcare record systems that 
integrates primary and secondary health care records. Categorization of these outcomes was 
performed blinded to the coronary CT angiography and PET data.  
Statistical analysis 
We assessed the distribution of data with the Shapiro-Wilk test. Continuous parametric variables 
were expressed as mean ± standard deviation, and non-parametric data were presented as median 
[interquartile interval]. Fisher's exact test or chi-squared test was used for analysis of categorical 
variables. The performance of machine-learning models and single clinical characteristics in 
predicting myocardial infarction was assessed using receiver operator characteristic (ROC) 
analysis, and the area under the curve (c-statistic) values were compared with the DeLong test 
(18). Statistical analysis was performed with SPSS version 24 (IBM SPSS Statistics for 
Windows, Version 24.0. Armonk, NY: IBM Corp) and R studio and R software version 4.01 (R 
Foundation for Statistical Computing, Vienna, Austria). A two-sided p<0.05 was considered 
statistically significant.   
Results 
All 293 study participants (65±9 years; 84% male) had established coronary artery disease and 
were on guideline recommended medical treatments (Table 1). Two-hundred and thirty-seven 
(81%) patients had a history of revascularization, 191 (65%) had multi-vessel obstructive 
coronary artery disease and the median coronary calcium score was 334 [76 to 804] AU. Over 
the 53 [40-59] months of follow-up, 22 subjects experienced a fatal (n=3) or non-fatal (n=19) 
myocardial infarction. 
The high burden of atherosclerosis was reflected in the quantitative plaque analysis derived from 
coronary CT angiography. The median total plaque volume was 1174 [716 to 1772] mm3 and 
consisted largely of non-calcified plaque (1099 [647 to 1574] mm3) with a substantial volume of 
low-attenuation plaque (88 [44 to 167] mm3). Over half of the study population (166 [56%]) had 
a low-attenuation plaque burden exceeding 4%. On PET, 109 (37.2%) patients presented with a 
high 18F-NaF coronary microcalcification activity (CMA>1.56; Figure 2).  
On receiver operator curve analysis, 18F-NaF CMA (c-statistic 0.76, 95% confidence interval 
(CI) 0.68 to 0.83; p<0.001), maximum 18F-NaF TBR (c-statistic 0.72, 95% CI 0.63 to 0.82; 
p<0.001) and maximum 18F-NaF SUV (c-statistic 0.70, 95% CI 0.59 to 0.81; p=0.002) were the 
only statistically significant predictors of myocardial infarction. In contrast, baseline clinical 
characteristics, luminal stenosis severity, qualitative or quantitative CT-derived variables were 
not significant predictors of myocardial infarction on their own (Table 2). However, when 
incorporated into machine-learning models, the aforementioned variables emerged as predictors 
of adverse events. While a model based on clinical characteristics only showed limited predictive 
performance with a c-statistic of 0.64 (95% CI 0.53-0.76), the quantitative plaque analysis-based 
machine-learning model outperformed the former with a c-statistic of 0.72 (95% CI 0.60-0.84, 
p=0.02) which was comparable to 18F-NaF CMA alone (p=0.47). Inclusion of clinical data 
improved the 18F-NaF CMA and quantitative plaque analysis-based models only slightly (0.77 
[95% CI 0.69-0.84] and 0.74 [95% CI 0.64-0.83] respectively). Importantly, after inclusion of all 
available data (clinical, quantitative plaque and 18F-NaF PET), we achieved an increase in model 
performance with a c-statistic of 0.85 (95% CI 0.79-0.91, p<0.001) which was higher than the 
quantitative CT plaque model (p=0.008) and the 18F-NaF CMA (p=0.01; Figures 3 and 4) as well 




We have built a machine-learning model for risk stratification in patients with established 
coronary artery disease. In our cohort of patients with advanced coronary atherosclerosis, we 
showed that risk prediction does not depend on cardiovascular risk scores, stenosis severity or 
CT calcium scoring. Rather the risk of myocardial infarction is primarily governed by the 
analysis of plaque type and plaque burden provided by coronary CT angiography and 
assessments of disease activity by 18F-NaF PET. Importantly, our machine learning approach has 
overcome the challenges posed by co-linearity of these variables and, for the first time, has 
demonstrated that this information is complementary and additive with the combination of both 
providing the most robust outcome prediction. If confirmed in further studies this comprehensive 
approach holds major promise in refining risk stratification of patients with established coronary 
artery disease, a population where such prediction is currently challenging. Importantly, such 
stratification in these patients can be achieved objectively with quantitative variables obtained on 
a single hybrid PET/CT acquisition.   
18F-NaF PET provides an assessment of vascular injury and disease activity across a wide 
spectrum of cardiovascular conditions including aortic stenosis, mitral annular calcification, 
abdominal aortic aneurysm, erectile dysfunction, bioprosthetic valve degeneration and coronary 
artery disease (2, 19-21). Indeed, baseline 18F-NaF PET is consistently associated with future 
disease progression and adverse events in each of these conditions. On the other hand, 
quantitative assessment of atherosclerotic plaque on contrast-enhanced CT angiography allows 
us to measure the burden of different types of plaque across the coronary arteries (4). We 
recently demonstrated that the low-attenuation plaque burden provides powerful prediction of 
myocardial infarction, outperforming cardiovascular risk scores, Agatston coronary artery 
calcium scoring, or the presence and severity of obstructive coronary artery disease. Whether 
these two exciting developments can be used in combination to further advance risk prediction 
was previously unknown.  
Using the information from these approaches and by leveraging machine-learning, we were able 
to build an integrated model for prediction of events in patients with established coronary artery 
disease, a group of patients where risk prediction is currently challenging. The XGBoost 
algorithm has been successfully implemented for risk prediction in a wide range of clinical 
scenarios (15, 22). It enables the incorporation of numerous predictors into the model even when 
these variables are correlated - a major limitation with conventional regression analyses. While 
we have previously shown that 18F-NaF uptake is associated with quantitative plaque analysis 
indices, our current analysis highlights the complementary prognostic information that PET and 
quantitative CT plaque assessments provide together (23, 24). Indeed, our machine learning 
model incorporating the information from these two modalities alongside clinical factors 
outperformed the individual components analyzed separately with a high c-statistic of 0.85. 
Importantly, our study also underscores that in patients with advanced coronary artery disease, 
markers of disease activity, plaque type and plaque burden provide superior risk prediction to 
clinical risk scores and conventional coronary calcium CT analyses. 
According to societal guidelines, patients with clinically manifest atherosclerotic arterial disease 
are considered to be at very high risk of a recurrent cardiovascular events and cardiovascular 
mortality. However, in everyday clinical practice, it is apparent that there is a wide distribution 
of actual risk for recurrent vascular events in patients with clinically established arterial disease. 
While the population of subjects with manifested coronary artery disease is rapidly growing, 
accurate risk prediction in this important population remains challenging.  The guideline 
recommended SMART risk score was shown to have only a moderate c-statistic (0.64-0.68), and 
there is a paucity of data regarding the role imaging could play in this cohort (1). In our study we 
have targeted this important high-risk population. We have demonstrated that quantitative plaque 
analysis measures and the coronary microcalcification activity considerably improve 
stratification of patients’ risk (c-statistic 0.85). In a conservative 10-fold cross testing machine 




With the limited number of patients and events, our findings require confirmation in future 
studies. Machine-learning models can perform better when trained within bigger datasets and 
therefore further studies are needed to confirm our findings and allow further testing to refine 
and to calibrate the machine-learning models. External validation of our findings in other cohorts 
is needed. While this is currently challenging given that 18F-NaF PET is an emerging technique, 
this will be possible in the future using outcome data from the Prediction of Recurrent Events 
With 18F-Fluoride (PREFFIR) study which is prospectively investigating the ability of 18F-NaF 
coronary PET and CT angiography to predict recurrent events in patients with multi-vessel 
disease and recent myocardial infarction. Since the majority of study participants had multivessel 
disease future studies should characterize the utility of 18F-NaF PET in single vessel disease 
patients. 
 
In conclusion, both 18F-NaF uptake and quantitative plaque analysis measures from contrast CT 
are strong predictors of outcome in patients with established coronary artery disease. Optimal 
risk stratification can be achieved by combining these imaging assessments of plaque type, 
burden and activity with clinical variables in a machine-learning model.  
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Age  65±9 
Men 245 (84%) 
Body-mass index (kg/m2), 29±5 
Systolic blood pressure (mm Hg) 141±20 
Diastolic blood pressure (mm Hg) 79±11 
Cardiovascular history History of acute coronary syndrome 161 (55.1%) 
History of percutaneous coronary 
intervention 
182 (62.3%) 
History of coronary artery bypass graft 
surgery 
48 (16.4%) 
History of angina 136 (46.6%) 
Recent acute coronary syndrome 
 
61 (21%) 
Cerebrovascular accident or transient 
ischemic attack 
9 (3.1%) 
Comorbidities/risk factors Hypertension 174 (59.6%) 
Hyperlipidemia 257 (88%) 





Atrial fibrillation 10 (3.4%) 
Peripheral vascular disease 16 (5.5%) 
Medications * Aspirin 268 (91.8%) 
Dual antiplatelet therapy 62 (21.2%) 
Statin 262 (89.7%) 
Beta Blocker 196 (67.1%) 
Angiotensin-converting enzyme 
inhibitor or angiotensin receptor 
blocker 
197 (67.4%) 
Insulin  4 (1.4 %) 
Oral diabetic medications 48 (16.4%) 
Calcium blockers 63 (21.6%) 
Diuretics 38 (16.0%) 
Biomarkers Total cholesterol (mg/dL) 159 [139-182] 
LDL cholesterol (mg/dL) 73 [46-93] 
HDL cholesterol (mg/dL) 46 [39-66] 
Triglycerides (mg/dL) 133 [97-204] 
Creatinine (mg/dL) 0.9 [0.8-1.0] 
Risk Scores SMART 18 [13-26] 
Computed Tomography – 
qualitative & non-contrast 
- Single vessel disease 
- Two vessel disease 
- Three vessel disease 





Coronary stent  218 (73.4%) 
Segment involvement score  5 [3-7] 
Segment involvement score >5 145 (73.5%) 
Coronary calcium score 334 [76-804] 










Computed tomography - 
quantitive 
Total plaque volume, mm3 1174 [716, 1772] 
Non-calcified plaque volume, mm3 1099 [647, 1574] 
Calcified plaque volume, mm3 77 [23, 180] 
Low-attenuation plaque volume, mm3 88 [44, 167] 
Total plaque burden, % 55 [49, 63] 
Non-calcified plaque burden, % 51 [45, 57] 
Calcified plaque burden, % 3.5 [1.4, 7.9] 
Low-attenuation plaque burden, % 4.4 [2.6, 7.0] 
Area stenosis, % 58 [47, 75] 
Contrast density difference, % 29 [24, 37] 
Ischemia score 31 [21, 47] 
18F-NaF PET CMA 0.66 [0-2.84] 
TBRmax 1.22 [1.1-1.42] 
SUVmax 1.44 [1.19, 1.71] 
Outcome Myocardial infarction 22 (7.5%) 
CMA – coronary microcalcification activity, PET – positron emission tomography, 18F-NaF – 
18F-sodium fluoride, SMART - Secondary Manifestations of ARTerial disease risk score, 
SUVmax – maximum standard uptake value, TBRmax – maximum target to background ratio 
Recent acute coronary syndrome was defined as an event within less than 14 days prior to PET 
imaging. 
 
Table 2. Prediction of myocardial infarction in patients with advanced coronary artery disease. 
Receiver operator curve modelling for prediction of myocardial infarction. 







Age 0.51 (0.35-0.67) 0.81 
Sex 0.51 (0.38-0.64) 0.84 
Body-mass index 0.58 (0.46-0.70) 0.23 
Systolic blood pressure 0.52 (0.37-0.67) 0.74 
Past Medical 
History 
Myocardial infarction 0.45 (0.33-0.58) 0.48 
Recent acute coronary syndrome 0.57 (0.43-0.71) 0.33 
Percutaneous coronary 
intervention 
0.53 (0.40-0.67) 0.66 
Coronary artery bypass graft 0.52 (0.39-0.65) 0.80 
Cerebrovascular accident 0.53 (0.40-0.67) 0.60 
Comorbidities Hypertension 0.47 (0.35-0.59) 0.57 
Hyperlipidaemia 0.48 (0.35-0.60) 0.61 
Diabetes 0.51 (0.37-0.65) 0.29 
Smoking 0.46 (0.32-0.60) 0.59 
Peripheral vascular disease 0.52 (0.39-0.66) 0.80 
Biomarkers Total cholesterol (mmol/L) 0.53 (0.38-0.68) 0.68 
LDL cholesterol (mmol/L) 0.59 (0.43-0.75) 0.18 
HDL cholesterol (mmol/L) 0.53 (0.38-0.67) 0.71 
Triglycerides (mmol/L) 0.57 (0.44-0.69) 0.33 
Creatinine (µmol/L) 0.54 (0.40-0.68) 0.54 





Multivessel disease 0.55 (0.42-0.68) 0.48 
Segment involvement score 0.56 (0.41-0.71) 0.40 
Coronary calcium score 0.51 (0.37-0.66) 0.87 




Total plaque volume 0.53 (0.39-0.67) 0.65 
Non-calcified plaque volume 0.54 (0.40-0.68) 0.53 
Calcified plaque volume 0.46 (0.33-0.58) 0.48 
Low-attenuation plaque volume 0.57 (0.41-0.72) 0.30 
Total plaque burden 0.45 (0.33-0.57) 0.42 
Non-calcified plaque burden 0.47 (0.35-0.59) 0.67 
Calcified plaque burden 0.41 (0.29-0.54) 0.16 
Low-attenuation plaque burden 0.61 (0.48-0.75) 0.071 
Area stenosis 0.48 (0.35-0.62) 0.79 
Contrast density difference 0.56 (0.40-0.71) 0.33 
Ischemia score 0.52 (0.38-0.65) 0.77 
18F-NaF PET CMA total 0.76 (0.68-0.83) <0.001 
TBRmax 0.72 (0.63-0.82) <0.001 
SUVmax 0.70 (0.59-0.81) 0.002 
CMA – coronary microcalcification activity, HDL – High density lipoprotein, LDL – low 
density lipoprotein, SD – standard deviation, PET – positron emission tomography, 18F-NaF – 
18F-sodium fluoride, SMART - Secondary Manifestations of ARTerial disease risk score, 
SUVmax – maximum standard uptake value, TBRmax – maximum target to background ratio. 
  
Figures 
Figure 1. Measuring Disease Activity Across the Coronary Vasculature with 18F-NaF 
Coronary Microcalcification Activity (CMA) and the Low Attenuation Plaque Burden with 
Quantitative Plaque Analysis. 3-Dimensional rendering of coronary CT angiography co-
registered with PET for evaluation of 18F-sodium fluoride uptake (blue and red; left panel). The 
coronary microcalcification activity (CMA) is a summary measure of 18F-NaF activity across the 
entire coronary vasculature as it includes all counts originating from the coronary arteries  3-
Dimensional rendering of CT angiography based quantitative plaque analysis with orange low 
attenuation plaque (LAP) and yellow calcified plaque. The low attenuation plaque burden was 
defined as the LAP volume x 100%/vessel volume.  
 
LAD – left anterior descending, LCX – left circumflex, RCA – Right coronary artery  
Figure 2. Case examples of quantitative plaque analysis on coronary CT angiography and 
18F-sodium fluoride positron emission tomography in patients with established coronary 
artery disease. Hybrid CT angiography and 18F-NaF positron emission tomography of coronary 
arteries in: (A) a 70-year-old male who presented with diffused largely non-calcified disease 
(middle panel in red) in the LAD and demonstrated increased 18F-NaF uptake in the LAD on 
positron emission tomography. (B) a 59-year-old male with mild LCX atherosclerosis, who 
presented with a high non-calcified plaque burden (middle panel in red) on CT angiography, 
significant 18F-NaF uptake and experienced a lateral non-ST-segment elevation myocardial 
infarction during follow-up.  
 
CMA – coronary microcalcification activity, LAD – left anterior descending, LCX – left 
circumflex, LAP – low attenuation plaque 
  
Figure 3. Prediction of myocardial infarction by machine-learning. A) Receiver operator 
curves for the risk of myocardial infarction: (1) 18F-sodium fluoride (18F-NaF) coronary 
microcalcification activity (CMA) alone; machine learning models based on (2) clinical data, (3) 
quantitative plaque analysis, (4) clinical + quantitative plaque analysis + 18F-NaF PET. The 
model based on both PET and quantitative CT-based plaque analysis data outperformed the 
clinical data and both unimodality models (p<0.01 for all). (B) Feature importance for the 
machine-learning model based on all variables. The solid bars and error bars represent the mean 
gain and standard deviation derived from the distribution of the importance within 10 folds of the 
cross testing, for each variable.  
 
*indicates a p<0.01 for a difference compared to 18F-NAF CMA, quantitative plaque, Clinical 
and CT (DeLong test) 
CMA – coronary microcalcification activity, SUV – standard uptake value, TBR – target to 
background ratio  
Figure 4. Calibration plot for the clinical + quantitative plaque analysis + 18F-NaF PET 
machine-learning XGBoost model. The calibration plot shows the relationship between the 
observed and predicted proportion of events, grouped by decile of risk. Our model showed very 
good calibration with the observed risk of myocardial infarction during follow-up. 
 
 
 
